Brokerages expect Inspire Medical Systems, Inc. (NYSE:INSP) to report sales of $22.50 million for the current fiscal quarter, Zacks Investment Research reports. Six analysts have provided estimates for Inspire Medical Systems' earnings, with estimates ranging from $22.00 million to $23.10 million. Inspire Medical Systems posted sales of $20.86 million during the same quarter last year, which suggests a positive year-over-year growth rate of 7.9%. The company is scheduled to report its next earnings report after the market closes on Monday, November 2nd.
On average, analysts expect that Inspire Medical Systems will report full-year sales of $90.23 million for the current fiscal year, with estimates ranging from $89.80 million to $91.30 million. For the next financial year, analysts expect that the company will post sales of $143.93 million, with estimates ranging from $131.06 million to $150.90 million. Zacks Investment Research's sales averages are a mean average based on a survey of analysts that cover Inspire Medical Systems.
Inspire Medical Systems (NYSE:INSP) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.88) earnings per share for the quarter, topping the Zacks' consensus estimate of ($1.08) by $0.20. The firm had revenue of $12.18 million for the quarter, compared to analyst estimates of $31.06 million. Inspire Medical Systems had a negative net margin of 69.69% and a negative return on equity of 35.04%. The business's quarterly revenue was down 32.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.32) earnings per share.
Several analysts recently commented on the stock. Oppenheimer restated a "sell" rating and set a $50.00 price target (up previously from $42.00) on shares of Inspire Medical Systems in a research report on Wednesday, August 5th. They noted that the move was a valuation call. BofA Securities lowered shares of Inspire Medical Systems from a "buy" rating to a "neutral" rating and set a $115.00 price target on the stock. in a research report on Thursday, August 6th. Robert W. Baird assumed coverage on shares of Inspire Medical Systems in a research report on Tuesday, September 1st. They set an "outperform" rating and a $130.00 price target on the stock. SVB Leerink raised their price target on shares of Inspire Medical Systems from $120.00 to $150.00 and gave the company an "outperform" rating in a research report on Wednesday, September 9th. Finally, JPMorgan Chase & Co. initiated coverage on shares of Inspire Medical Systems in a research report on Tuesday, September 22nd. They issued an "overweight" rating and a $148.00 target price on the stock. One investment analyst has rated the stock with a sell rating, five have given a hold rating and nine have assigned a buy rating to the stock. Inspire Medical Systems presently has a consensus rating of "Buy" and a consensus price target of $112.21.
NYSE:INSP opened at $123.97 on Tuesday. The firm has a market capitalization of $3.32 billion, a P/E ratio of -54.61 and a beta of 1.34. The company has a debt-to-equity ratio of 0.11, a current ratio of 20.48 and a quick ratio of 19.72. The company's fifty day moving average price is $125.72 and its 200-day moving average price is $96.54. Inspire Medical Systems has a 1-year low of $40.53 and a 1-year high of $135.20.
In other news, Director Marilyn C. Nelson sold 25,000 shares of the business's stock in a transaction that occurred on Thursday, October 8th. The shares were sold at an average price of $130.96, for a total transaction of $3,274,000.00. Following the completion of the sale, the director now owns 3,189 shares in the company, valued at approximately $417,631.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Chau Quang Khuong sold 116,570 shares of the business's stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $105.65, for a total transaction of $12,315,620.50. The disclosure for this sale can be found here. Insiders have sold a total of 425,714 shares of company stock valued at $46,701,241 in the last quarter. 6.60% of the stock is currently owned by company insiders.
Large investors have recently modified their holdings of the company. Marshall Wace North America L.P. acquired a new position in shares of Inspire Medical Systems during the 1st quarter worth $45,000. Parametric Portfolio Associates LLC grew its stake in shares of Inspire Medical Systems by 7.3% during the 1st quarter. Parametric Portfolio Associates LLC now owns 20,461 shares of the company's stock worth $1,233,000 after purchasing an additional 1,393 shares during the period. Nuveen Asset Management LLC grew its stake in shares of Inspire Medical Systems by 16.0% during the 1st quarter. Nuveen Asset Management LLC now owns 65,427 shares of the company's stock worth $3,944,000 after purchasing an additional 9,017 shares during the period. Geode Capital Management LLC grew its stake in shares of Inspire Medical Systems by 9.6% during the 1st quarter. Geode Capital Management LLC now owns 196,909 shares of the company's stock worth $11,869,000 after purchasing an additional 17,276 shares during the period. Finally, Wells Fargo & Company MN grew its stake in shares of Inspire Medical Systems by 136.6% during the 1st quarter. Wells Fargo & Company MN now owns 153,782 shares of the company's stock worth $9,271,000 after purchasing an additional 88,783 shares during the period.
Inspire Medical Systems Company Profile
Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.
See Also: What is the price-to-earnings growth (PEG) ratio?
Get a free copy of the Zacks research report on Inspire Medical Systems (INSP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
7 Stocks That Will Help You Forget About the Fed
Normally when the Federal Reserve (i.e. the Fed) makes an announcement, the market reacts predictably. That’s due, in large part, to the nature of what the Fed normally announces. Will interest rates go up, down, or remain unchanged? And for their part, the markets have a pretty good idea what the Fed will do before they do it.
But the Fed’s announcement of August 26 was a little different. They talked briefly about interest rates (they’re staying really low for a long time). But they were more concerned about inflation. Well, the Fed is always concerned about inflation, but this time they really mean it. Basic economics says that low-interest rates should spur inflation.
However, the market has been defying conventional wisdom and the Fed is not getting the inflation they want. So the Fed has basically said that they’re letting inflation go rogue. If it goes above their target 2% rate, so be it. The Fed is done trying to hit a target.
At first, the markets cheered the news. Not only was the Fed not taking away the punch bowl, but they were also going to keep the low rate liquidity going for a long time!
But after a little while to digest things, investors are realizing they have to be grown-ups about this. And now investors are considering how to rebalance their portfolios for the remainder of 2020.
I don’t know about them, but if I were you I would target companies that have a high free cash flow (FCF). Whether it’s your personal finances or in evaluating a stock, cash flow is your friend.
When a corporation has high FCF, they have more strong growth in good markets and more flexibility during when the economy is weaker.
As institutional investors come back into the market, it’s time for you to reposition your portfolio for whatever comes next.
View the "7 Stocks That Will Help You Forget About the Fed".